FIGURE 2.

Ustekinumab and guselkumab inhibit IL-23–induced cytokine production in vitro.

(A–C) were harvested from female C57BL/6 mice, and single-cell suspensions were prepared. rhIL-23 was preincubated with guselkumab, ustekinumab, or an isotype control Ab and then added to cells. Cells were incubated for 3 d. Supernatants were assayed by ELISA for IL-23–induced (A) IL-17A, (B) IL-17F, and (C) IL-22 production. (D) Human NK92MI cells were plated, and rhIL-12 was preincubated with guselkumab, ustekinumab, or an isotype control Ab and added to cells. Cell supernatants were collected and assayed by cytokine-specific ELISA for IL-12–induced (D) IFN-γ production. Data shown are means of quadruplicate (A–C) or duplicate (D) samples.